Metraipolis › archive › dc_ede6bd013909

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase… — Europe PMC PMID:40972226

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40972226
DOI
10.1016/j.ebiom.2025.105940
License (as archived)
solo-consultazione
Archived
2026-11-09T21:02:26.314Z
SHA-256 of the archived text
452a084488478707d69c6510420d48360156ada22710b4c334a0ab46fd3e7187
Stable URL of this page
https://metraipolis.com/documento/dc_ede6bd013909

How to cite

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase… — Europe PMC PMID:40972226 — Europe PMC (en), https://europepmc.org/article/MED/40972226 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ede6bd013909 (Metraipolis archive dc_ede6bd013909, sha256 452a084488478707d69c6510420d48360156ada22710b4c334a0ab46fd3e7187)
BibTeX
@misc{dcede6bd013909,
  title = {Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase… — Europe PMC PMID:40972226},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40972226},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ede6bd013909; sha256 452a084488478707d69c6510420d48360156ada22710b4c334a0ab46fd3e7187},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40972226. Agents can read the archived copy with the MCP tool read_document.